Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
Total Valuation
Compass Therapeutics has a market cap or net worth of $866.19M. The enterprise value is $380.71M.
Market Cap$866.19M
Enterprise Value$380.71M
Share Statistics
Compass Therapeutics has 177,862,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding177,862,100
Owned by Insiders21.17%
Owned by Institutions4.52%
Financial Efficiency
Compass Therapeutics’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -42.94%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-42.94%
Return on Capital Employed (ROCE)-0.43
Revenue Per Employee24.29K
Profits Per Employee-1.41M
Employee Count35
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Compass Therapeutics is ―. Compass Therapeutics’s PEG ratio is -0.44.
PE Ratio―
PS Ratio233.89
PB Ratio1.59
Price to Fair Value1.59
Price to FCF-4.43
Price to Operating Cash Flow-20.29
PEG Ratio-0.44
Income Statement
In the last 12 months, Compass Therapeutics had revenue of 850.00K and earned -49.38M in profits. Earnings per share was -0.36.
Revenue850.00K
Gross Profit850.00K
Operating Income-56.63M
Pretax Income-49.38M
Net Income-49.38M
EBITDA-54.87M
Earnings Per Share (EPS)-0.36
Cash Flow
In the last 12 months, operating cash flow was -34.20M and capital expenditures -11.00K, giving a free cash flow of -34.22M billion.
Operating Cash Flow-34.20M
Free Cash Flow-34.22M
Free Cash Flow per Share-0.19
Dividends & Yields
Compass Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.93
52-Week Price Change226.85%
50-Day Moving Average4.04
200-Day Moving Average2.94
Relative Strength Index (RSI)67.22
Average Volume (3m)1.90M
Important Dates
Compass Therapeutics upcoming earnings date is Feb 27, 2026, Before Open (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateFeb 27, 2026
Ex-Dividend Date―
Financial Position
Compass Therapeutics as a current ratio of 14.96, with Debt / Equity ratio of 0.00%
Current Ratio14.96
Quick Ratio14.96
Debt to Market Cap0.00
Net Debt to EBITDA0.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Compass Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Compass Therapeutics EV to EBITDA ratio is -2.95, with an EV/FCF ratio of -3.61.
EV to Sales190.54
EV to EBITDA-2.95
EV to Free Cash Flow-3.61
EV to Operating Cash Flow-3.61
Balance Sheet
Compass Therapeutics has $219.90M in cash and marketable securities with $9.87M in debt, giving a net cash position of $210.03M billion.
Cash & Marketable Securities$219.90M
Total Debt$9.87M
Net Cash$210.03M
Net Cash Per Share$1.18
Tangible Book Value Per Share$0.91
Margins
Gross margin is 0.00%, with operating margin of -6661.76%, and net profit margin of -5808.82%.
Gross Margin0.00%
Operating Margin-6661.76%
Pretax Margin-5808.82%
Net Profit Margin-5808.82%
EBITDA Margin-6455.53%
EBIT Margin-6661.76%
Analyst Forecast
The average price target for Compass Therapeutics is $15.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$15.33
Price Target Upside216.08% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-100.00%
EPS Growth Forecast-28.79%